Tuberculosis Therapeutics Market Introduction and Overview
According to SPER market research, ‘Global Tuberculosis Therapeutics Market Size- By Disease Type, By Therapy, By Route of Administration – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Tuberculosis Therapeutics Market is predicted to reach 3.77 billion by 2034 with a CAGR of 5.38 %.
Drugs and treatment plans intended to prevent, manage, and cure tuberculosis (TB), a communicable bacterial infection brought on by Mycobacterium tuberculosis, are referred to as TB therapies. Antibiotics such isoniazid, rifampicin, ethambutol, and pyrazinamide are part of the standard treatment, which is usually given over a period of six months. Shorter treatment durations, better drug formulations, and the targeting of drug-resistant TB strains such as extensively drug-resistant TB (XDR-TB) and multidrug-resistant TB (MDR-TB) are the main goals of advanced treatments.
Restraints:The growing incidence of extensively drug-resistant (XDR-TB) and multidrug-resistant (MDR-TB) market for TB treatments. Effective TB management is hampered by high drug costs, poor healthcare infrastructure, and restricted access to cutting-edge therapies in low-income nations. Inadequate research funding and drawn-out medication approval procedures impede the creation of innovative medicines. Drug resistance is also influenced by patient non-compliance brought on by extended treatment plans.
Scope of the Report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Disease Type, By Therapy, By Route of Administration.
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.
Companies Covered
Cipla Limited, GlaxoSmithKline, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd. and others.
Tuberculosis Therapeutics Market Segmentation:
By Disease Type:Based on the Disease Type, Global Tuberculosis Therapeutics Market is segmented as; Active TB, Latent TB.
By Therapy:Based on the Therapy, Global Tuberculosis Therapeutics Market is segmented as; First-Line Therapy, Second-Line Therapy.
By Route of Administration:Based on the Route of Administration, Global Tuberculosis Therapeutics Market is segmented as; Oral, Parenteral, Others.
By Region:This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global Tuberculosis Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tuberculosis Therapeutics Market
- 7. Global Tuberculosis Therapeutics Market, By Disease Type (USD Million) 2021-2034
- 7.1. Active TB
- 7.2. Latent TB
- 8. Global Tuberculosis Therapeutics Market, By Therapy (USD Million) 2021-2034
- 8.1. First-Line Therapy
- 8.2. Second-Line Therapy
- 9. Global Tuberculosis Therapeutics Market, By Route of Administration (USD Million) 2021-2034
- 9.1. Oral
- 9.2. Parenteral
- 9.3. Others
- 10. Global Tuberculosis Therapeutics Market, (USD Million) 2021-2034
- 10.1. Global Tuberculosis Therapeutics Market Size and Market Share
- 11. Global Tuberculosis Therapeutics Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
- 12. Company Profile
- 12.1. Cipla Limited
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. GlaxoSmithKline
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Johnson & Johnson
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Lupin Limited
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Merck & Co., Inc.
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Novartis AG
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Pfizer Inc.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Sanofi
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Sun Pharmaceutical Industries Ltd.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Others
- 13. Conclusion
- 14. List of Abbreviations
- 15. Reference Links
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook